Arix Bioscience Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 9
- Investments
- 29
- Portfolio
- 16
- Exits
- 10
Arix Bioscience General Information
Description
Founded in 2016, Arix Bioscience is a listed venture capital firm based in London, United Kingdom. The firm invests in seed-stage companies, preclinical and clinical-stage assets, private or public companies across biotech, healthcare and life science sectors.
Contact Information
Website
Year Founded
2016
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 20 Berkeley Square
- London W1J 6EQ
- England, United Kingdom
+44 020 0000 0000
Arix Bioscience Investments & Acquisitions (29)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| VelosBio | 02-Jul-2020 | Early Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 00000000 00000 00.0 |
| 00000000 | 08-May-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 00000000 00.0 |
| 00000 | 01-Feb-2020 | 00000 00000 | 000.00 | Biotechnology | Clinical Trials - Phase 2 | 0000 0000 |
| 000000 000 | 27-Jan-2020 | 00000 00000 | 000.00 | Biotechnology | Startup | 00000000 00000 00.0 |
| 000000 | 09-Jan-2020 | 00000 00000 | 000.00 | Pharmaceuticals | Generating Revenue | 000000 00000000 00.0 |
| 00000 000000000000 | 30-Sep-2019 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000000 00000 00.0 |
| 0000 000 | 30-Apr-2019 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 00000000 00000 00.0 |
| 0000 00000000000 | 02-Apr-2019 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 0000 0000 |
| Harpoon Therapeutics | 08-Feb-2019 | IPO | 0000 | Biotechnology | Generating Revenue/Not Profitable | 0000 0000 |
| Aura Biosciences | 13-Dec-2018 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue | 0000 0000 |
Arix Bioscience Exits (10)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| VelosBio | 18-Dec-2020 | Merger/Acquisition | 00.000 |
| 000000 00000000000 | 26-Oct-2020 | 000000 0000000000 | 000.00 |
| 00000 | 12-Mar-2020 | 000 | 000.00 |
| 0000000 | 22-Jan-2020 | 000000000 00000000 | |
| 0000000 | 11-Apr-2019 | 000000 0000000000 | 00000 |
| 0000000 0000000000 | 08-Feb-2019 | 000 | 0000 |
| 00000000 000000000 | 19-Oct-2018 | 000 | 0000 |
| 0000000 | 22-Jun-2018 | 000 | 00000 |
| Iterum Therapeutics | 25-May-2018 | IPO | 0000 |
| Verona Pharma | 26-Apr-2017 | Public Investment 2nd Offering | 0000 |
Arix Bioscience Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialArix Bioscience Team (21)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Robert Lyne | Chief Operating Officer & General Counsel | London, United Kingdom | |||
| Christian Schetter Ph.D | Managing Director | 0 | London, United Kingdom | ||
| Jonathan Tobin Ph.D | Managing Director | 0 | 0 | 0 | London, United Kingdom |
| John Cassidy Ph.D | Principal | 0 | London, United Kingdom | ||
| Michelle Keating | Financial Controller | London, United Kingdom |
Arix Bioscience Co-Investors (83)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 6 | 0 | 0 |
|
|
| Lundbeckfond Ventures | 0 | 0 |
|
|
|
| Cormorant Asset Management | 0 | 0 | 0 |
|
|
| Sofinnova Investments | 0 | 0 | 0 |
|
|
| Pappas Capital | 0 | 0 | 0 |
|
|